应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
DNLI Denali Therapeutics Inc.
休市中 05-10 16:00:00 EDT
18.31
-0.36
-1.93%
盘后
18.31
+0.00
0.00%
16:20 EDT
最高
18.95
最低
18.27
成交量
76.32万
今开
18.84
昨收
18.67
日振幅
3.64%
总市值
26.11亿
流通市值
22.55亿
总股本
1.43亿
成交额
1,407万
换手率
0.62%
流通股本
1.23亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
美国研究综述-新月能源、罗克韦尔自动化、Transdigm 集团
Reuters · 05-09
美国研究综述-新月能源、罗克韦尔自动化、Transdigm 集团
Wedbush:维持Denali Therapeutics(DNLI.US)评级,由优于大市调整至优于大市评级, 目标价由31.00美元调整至30.00美元。
智通财经 · 05-08
Wedbush:维持Denali Therapeutics(DNLI.US)评级,由优于大市调整至优于大市评级, 目标价由31.00美元调整至30.00美元。
美国研究综述-欧特克、Hireright Holdings、斑马技术公司
Reuters · 02-19
美国研究综述-欧特克、Hireright Holdings、斑马技术公司
嗡嗡声--美国股票走势-Super Micro Computer、Kinsale Capital、Kinnate Biopharma
Reuters · 02-16
嗡嗡声--美国股票走势-Super Micro Computer、Kinsale Capital、Kinnate Biopharma
暂无数据
公司概况
公司名称:
Denali Therapeutics Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Denali Therapeutics Inc.于2013年10月在特拉华州注册成立。他们的目标是发现和开发治疗方法来打败退化问题。神经退化代表了他们那个时代最重要的未得到满足的医疗需求之一,比如阿尔茨海默病,帕金森病疾病,肌萎缩性侧索硬化症或ALS,以及其他神经退化性疾病。这些疾病对患者和社会的负担是巨大的。他们相信现在正是他们利用强有力和雄心勃勃的努力来打败神经退化的正确时机。他们相信,他们可以在一个很少成功的领域取得了成就,因为他们拥有丰富的成功经验、热忱的科学家和药物开发者团队,他们专注的科学战略,以及他们专有的血脑屏障(BBB)平台输送技术。他们正在开发广泛的神经退行性疾病靶向治疗候选药物组合,并且最近开始了他们的第一个临床试验。他们于2015年5月开始运营。
发行价格:
--
{"stockData":{"symbol":"DNLI","market":"US","secType":"STK","nameCN":"Denali Therapeutics Inc.","latestPrice":18.31,"timestamp":1715371200000,"preClose":18.67,"halted":0,"volume":763171,"hourTrading":{"tag":"盘后","latestPrice":18.31,"preClose":18.31,"latestTime":"16:20 EDT","volume":34848,"amount":638066.88,"timestamp":1715372400685},"delay":0,"floatShares":123148949,"shares":142609036,"eps":-0.976201,"marketStatus":"休市中","marketStatusCode":7,"change":-0.36,"latestTime":"05-10 16:00:00 EDT","open":18.84,"high":18.95,"low":18.27,"amount":14066431.313589,"amplitude":0.036422,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.976201,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1715587200000},"adr":0,"listingDate":1512709200000,"adjPreClose":18.67,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":18.65,"preClose":18.67,"latestTime":"09:29 EDT","volume":671,"amount":12520.649977000001,"timestamp":1715347799999},"postHourTrading":{"tag":"盘后","latestPrice":18.31,"preClose":18.31,"latestTime":"16:20 EDT","volume":34848,"amount":638066.88,"timestamp":1715372400685},"volumeRatio":0.6012260687568763},"requestUrl":"/m/hq/s/DNLI/tweets","defaultTab":"tweets","newsList":[{"id":"2434594580","title":"美国研究综述-新月能源、罗克韦尔自动化、Transdigm 集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2434594580","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2434594580?lang=zh_cn&edition=full","pubTime":"2024-05-09 14:54","pubTimestamp":1715237640,"startTime":"0","endTime":"0","summary":" 路透5月9日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价,包括新月能源、罗克韦尔自动化和 Transdigm 集团。要闻 * 新月能源 :Gerdes Energy Research将其评级从 \"买入 \"下调至 \"中性\"。* Transdigm Group Inc :摩根大通将目标价从1175美元上调至1350美元 以下是路透周四报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433727865","title":"Wedbush:维持Denali Therapeutics(DNLI.US)评级,由优于大市调整至优于大市评级, 目标价由31.00美元调整至30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2433727865","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433727865?lang=zh_cn&edition=full","pubTime":"2024-05-08 22:26","pubTimestamp":1715178382,"startTime":"0","endTime":"0","summary":"Wedbush:维持Denali Therapeutics(DNLI.US)评级,由优于大市调整至优于大市评级, 目标价由31.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082226268ae8f96b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082226268ae8f96b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2412972660","title":"美国研究综述-欧特克、Hireright Holdings、斑马技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2412972660","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412972660?lang=zh_cn&edition=full","pubTime":"2024-02-19 14:40","pubTimestamp":1708324852,"startTime":"0","endTime":"0","summary":" 路透社2月19日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价,其中包括 Autodesk、Hireright Holdings 和斑马技术公司。要闻 * 欧特克公司 :贝伦贝格将目标价从250美元上调至290美元 * Hireright Holdings Corp :Needham将目标价从 \"买入 \"下调至 \"持有 * 斑马技术公司 :Baird将目标价从292美元上调至312美元 以下是路透社周一报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411566281","title":"嗡嗡声--美国股票走势-Super Micro Computer、Kinsale Capital、Kinnate Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2411566281","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411566281?lang=zh_cn&edition=full","pubTime":"2024-02-16 23:53","pubTimestamp":1708098808,"startTime":"0","endTime":"0","summary":" * 个股异动的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 2月16日 - 周五,华尔街主要股指走低,此前一份热度高于预期的生产者物价报告打压了市场对美国联邦储备委员会 即将降息的猜测。美东时间10:31,道琼斯工业平均指数 下跌0.27%,报38,669.2点。标准普尔500指数 下跌0.39%,报5,010.17点;纳斯达克综合指数 下跌0.75%,报15,787.267点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.denalitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0683},{"period":"1month","weight":-0.006},{"period":"3month","weight":0.0144},{"period":"6month","weight":0.1289},{"period":"1year","weight":-0.3388},{"period":"ytd","weight":-0.1468}],"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0392},{"period":"6month","weight":0.1821},{"period":"1year","weight":0.2638},{"period":"ytd","weight":0.0958}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Denali Therapeutics Inc.于2013年10月在特拉华州注册成立。他们的目标是发现和开发治疗方法来打败退化问题。神经退化代表了他们那个时代最重要的未得到满足的医疗需求之一,比如阿尔茨海默病,帕金森病疾病,肌萎缩性侧索硬化症或ALS,以及其他神经退化性疾病。这些疾病对患者和社会的负担是巨大的。他们相信现在正是他们利用强有力和雄心勃勃的努力来打败神经退化的正确时机。他们相信,他们可以在一个很少成功的领域取得了成就,因为他们拥有丰富的成功经验、热忱的科学家和药物开发者团队,他们专注的科学战略,以及他们专有的血脑屏障(BBB)平台输送技术。他们正在开发广泛的神经退行性疾病靶向治疗候选药物组合,并且最近开始了他们的第一个临床试验。他们于2015年5月开始运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.022693},{"month":2,"riseRate":0.428571,"avgChangeRate":0.015921},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.073957},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.018616},{"month":5,"riseRate":0.857143,"avgChangeRate":0.081169},{"month":6,"riseRate":0.5,"avgChangeRate":0.02869},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.067919},{"month":8,"riseRate":0.5,"avgChangeRate":0.072065},{"month":9,"riseRate":0.5,"avgChangeRate":0.005452},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.051994},{"month":11,"riseRate":0.666667,"avgChangeRate":0.156372},{"month":12,"riseRate":0.5,"avgChangeRate":0.070849}],"exchange":"NASDAQ","name":"Denali Therapeutics Inc.","nameEN":"Denali Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Denali Therapeutics Inc.(DNLI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Denali Therapeutics Inc.(DNLI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Denali Therapeutics Inc.,DNLI,Denali Therapeutics Inc.股票,Denali Therapeutics Inc.股票老虎,Denali Therapeutics Inc.股票老虎国际,Denali Therapeutics Inc.行情,Denali Therapeutics Inc.股票行情,Denali Therapeutics Inc.股价,Denali Therapeutics Inc.股市,Denali Therapeutics Inc.股票价格,Denali Therapeutics Inc.股票交易,Denali Therapeutics Inc.股票购买,Denali Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Denali Therapeutics Inc.(DNLI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Denali Therapeutics Inc.(DNLI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}